+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Teva

The publisher explores Teva’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Teva will look to build on the launches of Austedo and Ajovy to counter the erosion of Copaxone, the litigation risk around opioids in the US, and the company’s high debt burden.
  • Key themes - [1] Launch of Austedo is going extremely well, with favorable national formulary coverage and growth in Huntington’s disease, chorea, and tardive dyskinesia [2] Teva’s North American generics business will remain broadly stable over the forecast period [3] Copaxone sales will continue to fall as generics erode its market share.
Model updates (6 November 2020)
  • Copaxone forecast adjusted higher
  • Ajovy forecast adjusted lower
  • Austedo forecast adjusted lower.
Model updates (5 August 2020)
  • Ajovy forecast adjusted lower
  • Biosimilars forecast removed due to Teva including this revenue in its Generics segment
  • Generics forecast adjusted higher to account for biosimilar revenues.
Model updates (7 May 2020)
  • Treanda/Bendeka forecast adjusted higher due to patent resolution extending exclusivity until 2031
  • Ajovy forecast adjusted lower
  • Biosimilars forecast adjusted higher due to launches of Truxima and Herzuma.
Model updates (12 February 2020)
  • Copaxone forecast adjusted higher as pace of generic decline starts to abate
  • Austedo forecast adjusted higher due to continued adoption.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll